Evidence map›Paper›PMID 39939497›Full record

ArticleImmunologic research2025

Immunization with recombinant HPV16-E7d in fusion with Flagellin as a cancer vaccine: Effect of antigen-adjuvant orientation on the immune response pattern.

Meysam Gachpazan, Ali Ahmadnia Alashti, Hamid Reza Jahantigh, Majid Moghbeli, Sobhan Faezi, Seyed Younes Hosseini, Mohammad Mahdi Eftekharian, Maryam Nasimi, Farhad Motavalli Khiavi, Alireza Rahimi and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Meysam GachpazanAdvanced Therapy Medicinal Product (ATMP) Department, Breast Cancer Research Center Academic Center for Education, Culture and Research (ACECR)Vanak Sq, Motamed Cancer Institute, South Gandi Ave, P.O. BOX, Tehran, 15179/64311, NO.146, Iran.
Ali Ahmadnia AlashtiAdvanced Therapy Medicinal Product (ATMP) Department, Breast Cancer Research Center Academic Center for Education, Culture and Research (ACECR)Vanak Sq, Motamed Cancer Institute, South Gandi Ave, P.O. BOX, Tehran, 15179/64311, NO.146, Iran.
Hamid Reza JahantighDepartment of Pathology, Faculty of Medicine, Emory University, Atlanta, GA, 30033, USA.
Majid MoghbeliDepartment of Biology, Islamic Azad University of Damghan Branch, Damghan, Iran.
Sobhan FaeziMedical Biotechnology Research Center, School of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran.
Seyed Younes HosseiniDepartment of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad Mahdi EftekharianDepartment of Immunology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Maryam NasimiDepartment of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Farhad Motavalli KhiaviMedical Biotechnology Research Center, AJA University of Medical Sciences, Etemad Zadeh Street, Fatemi-Gharbi Street, Tehran, Iran.
Alireza RahimiDepartment of Recombinant Products, Production and Research Complex, Pasteur Institute of Iran, Tehran, Iran.
Reza Arabi MianroodiDepartment of Research and Development, Research and Production Complex, Pasteur Institute of Iran, Tehran, Iran.
Mahdi PakjooAdvanced Therapy Medicinal Product (ATMP) Department, Breast Cancer Research Center Academic Center for Education, Culture and Research (ACECR)Vanak Sq, Motamed Cancer Institute, South Gandi Ave, P.O. BOX, Tehran, 15179/64311, NO.146, Iran.
Morteza TaghizadehDepartment of Medical Vaccine, Agricultural Research, Education and Extension Organization (AREEO), Razi Vaccine and Serum Research Institute, Karaj, Iran. M.taghizadeh@rvsri.ac.ir.
Maria TempestaDepartment of Veterinary Medicine, Animal Health and Zoonosis PhD Course, University of Bari, Bari, Italy.
Mehdi MahdaviAdvanced Therapy Medicinal Product (ATMP) Department, Breast Cancer Research Center Academic Center for Education, Culture and Research (ACECR)Vanak Sq, Motamed Cancer Institute, South Gandi Ave, P.O. BOX, Tehran, 15179/64311, NO.146, Iran. Mahdavivac@gmail.com.ORCID http://orcid.org/0000-0003-4478-5957

Funding

Pasteur Institute of Iran 595
6 · The paper itself

Abstract

Human papillomavirus (HPV) is the leading cause of cervical cancer worldwide. The pathogenesis of HPV is mainly dependent on its E7 and E6 proteins. Up to now, different adjuvants have been used to enhance the efficacy of the immune response against these two proteins. In this study, Flagellin (FLA) was used as adjuvant to test adjuvant activity and also see whether its orientation of attachment can affect the immune response pattern. The E7d-FLA and FLA-E7d in pET28a vector were constructed and then the recombinant proteins were expressed in E. coli BL21 (DE3) bacteria under IPTG induction. The expression of recombinant E7d-FLA and FLA-E7d proteins is confirmed by SDS-PAGE and western blot. Then, recombinant fusion proteins were purified using a nickel-nitrilotriacetic acid (Ni-NTA) column. The recombinant proteins were checked for endotoxin contamination and then quantified by Bradford. Eight-to-ten-week-old male Balb/C mice were immunized subcutaneously with 10 µg recombinant E7d-FLA, FLA-E7d and HPV16E7d vaccine on days 0, 14 and 28. In addition, PBS and FLA groups were considered as control group. Then, spleen cells were harvested to assess lymphocyte proliferation and IFN-γ, IL-4 and IL-17 cytokines. In addition, mice sera were used for specific total IgG and IgG1, IgG2a, IgG2b and IgM antibodies assessment by ELISA. The results show that E7d-FLA is more potent in the induction of lymphocyte proliferation, CTL response and specific total IgG, IgG2a and IgG2b response, while the FLA-E7d vaccine was associated with more IFN-γ, and IL-17 cytokine response. The results of this study proved the ability of FLA as an adjuvant in fusion with E7d in the induction of cellular and humoral immune responses. In addition, it also emphasizes that antigen-adjuvant orientation can affect the immune response strength and polarization against HPV E7d vaccine candidate. HIGHLIGHTS: Flagellin is attached to HPV-16 E7d at the C- or N-terminus to create E7d-FLA and FLA-E7d candidate vaccines. The E7d-FLA vaccine showed a significant increase in lymphocyte proliferation, CTL response and IgG response versus FLA-E7d vaccine. The FLA-E7d vaccine is associated with a significant increase in IFN-γ and IL-17 cytokines response versus E7d-FLA vaccine. It seems that that antigen-adjuvant orientation is an important parameter in the strength and polarization of immune response in HPV E7d vaccine candidate.

Indexed as

Cancer VaccinesFlagellinHuman papillomavirus 16Papillomavirus E7 ProteinsPapillomavirus InfectionsPapillomavirus VaccinesUterine Cervical NeoplasmsAdjuvants, ImmunologicAnimalsAntibodies, ViralCytokinesHumansImmunizationMaleMiceMice, Inbred BALB CAdjuvants, ImmunologicAntibodies, ViralCancer VaccinesCytokinesFlagellinoncogene protein E7, Human papillomavirus type 16Papillomavirus E7 ProteinsPapillomavirus VaccinesRecombinant Fusion ProteinsAdjuvantFlagellaFusion vaccineHPV16 E7dImmune response patterns

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.